Stocks TelegraphStocks Telegraph
Screener NEW

LGND Stock Price History and Quote Analysis Insights for Investors

NASDAQ : LGND

Ligand Pharmaceuticals Incorporated

$116.91
3.4+3.00%
At Close 4:00 PM
73.75
B-ESG ScoreESG Rating
Loading...

Stock Price Today

Ligand Pharmaceuticals Incorporated (LGND) stock surged +3.00%, trading at $116.91 on NASDAQ, up from the previous close of $113.51. The stock opened at $113.70, fluctuating between $113.59 and $117.28 in the recent session.

Stock Snapshot

113.51
Prev. Close
113.7
Open
2.21B
Market Cap
18.9M
Number of Shares
113.59
Day Low
117.275
Day High
46.95
P/E Ratio
97.77%
Free Float in %
2.49
EPS (TTM)
40.13
Book Value
-0.24
Cash Flow per Share
107.19K
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Dec 13, 2024113.70117.28113.59116.91107.19K
Dec 12, 2024120.26120.94113.39113.53102.68K
Dec 11, 2024121.18122.07118.48120.36113.05K
Dec 10, 2024116.81119.77114.00118.60113.52K
Dec 09, 2024124.78125.50114.15116.52156.95K
Dec 06, 2024124.11127.86122.89124.83121.3K
Dec 05, 2024120.08124.24120.08123.51114.83K
Dec 04, 2024120.01123.00119.73120.9873.31K
Dec 03, 2024122.61123.32119.50119.9381.24K
Dec 02, 2024121.99124.00119.18122.8283.36K
Nov 29, 2024123.44124.34120.01121.4772.1K
Nov 27, 2024123.65125.00121.06122.5588.94K
Nov 26, 2024120.62124.44119.78124.33182.79K
Nov 25, 2024119.74122.63119.04120.62153.7K
Nov 22, 2024116.22120.00116.22119.1993.21K
Nov 21, 2024112.80118.12112.06116.8183.31K
Nov 20, 2024111.59112.00109.53111.56133.6K
Nov 19, 2024110.72112.27109.78111.8098.2K
Nov 18, 2024110.87113.04109.44111.67125.81K
Nov 15, 2024116.52116.52110.32111.71107.8K

Contact Details

EmeryVille, CA 94608

United States

Website: https://www.ligand.comContact: 858 550 7500

About Company

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Company Information

Employees58
Beta0.9
Sales or Revenue$131.31M
5Y Sales Change%-0.274%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Ligand Pharmaceuticals Incorporated (LGND) stock price?

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) stock price is $116.91 in the last trading session. During the trading session, LGND stock reached the peak price of $117.28 while $113.59 was the lowest point it dropped to. The percentage change in LGND stock occurred in the recent session was 3% while the dollar amount for the price change in LGND stock was $3.40.

LGND's industry and sector of operation?

The NASDAQ listed LGND is part of Biotechnology industry that operates in the broader Healthcare sector. Ligand Pharmaceuticals Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LGND?

Ms. Audrey Warfield-Graham
Chief People Officer
Mr. Todd Pettingill
Director of Corporation Devel.
Mr. Matthew E. Korenberg
Pres & Chief Operating Officer
Dr. Vincent D. Antle
Senior Vice President of Technical Operations & QA - Capitsol
Mr. Todd C. Davis
Chief Executive Officer & Director
Mr. John L. Higgins
Executive Director
Simon Latimer
Head of Investor Relations
Dr. Keith Marschke
Senior Vice President of Biology & Scientific Affairs
Mr. Octavio Espinoza
Chief Financial Officer
Mr. Patrick Lucy
Senior Vice President & CBO Protein Expression Bus.
Mr. Andrew T. Reardon J.D.
Chief Legal Officer & Sec.
Mr. Todd C. Davis Ph.D.
Chief Executive Officer & Director

How LGND did perform over past 52-week?

LGND's closing price is 77.57% higher than its 52-week low of $65.84 where as its distance from 52-week high of $129.90 is -10%.

How many employees does LGND have?

Number of LGND employees currently stands at 58.

Link for LGND official website?

Official Website of LGND is: https://www.ligand.com

How do I contact LGND?

LGND could be contacted at phone 858 550 7500 and can also be accessed through its website. LGND operates from 5980 Horton Street, EmeryVille, CA 94608, United States.

How many shares of LGND are traded daily?

LGND stock volume for the day was 107.19K shares. The average number of LGND shares traded daily for last 3 months was 113.2K.

What is the market cap of LGND currently?

The market value of LGND currently stands at $2.21B with its latest stock price at $116.91 and 18.9M of its shares outstanding.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph